Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

Trial Profile

Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Ensartinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms eXalt2; Xalt2
  • Sponsors Xcovery Holdings
  • Most Recent Events

    • 18 Oct 2017 Results (Data cut off: 1 apr 2017, n=15) assessing response to Ensartinib therapy in patients with Alk+ NSCLC patients, presented at the 18th World Conference on Lung Cancer.
    • 07 Dec 2016 Results of plasma genotyping and response in patients with ALK+ non-small cell lung cancer (n=83) presented at the 17th World Conference on Lung Cancer
    • 01 Nov 2016 Results (n=83) published in the Journal of Thoracic Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top